Quantcast

Latest Glomerulonephritis Stories

2014-08-11 20:23:57

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Glomerulonephritis-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278516/-Glomerulonephritis-Pipeline-Insights-2014.htmlSUMMARYDelveInsight's, "Glomerulonephritis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under...

2014-07-28 20:24:33

HAYWARD, Calif., July 28, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014. Net loss for the three months ended June 30, 2014 was $7.3 million, compared to $8.3 million for the same period in 2013. The decrease in net loss is a direct result of a decrease in interest expense in the current period. Net loss for the six months ended June 30, 2014 was $15.2 million,...

2014-07-10 04:21:24

STOCKHOLM, July 10, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon(R) issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. Nefecon is a potential disease-modifying treatment for patients with primary IgA nephropathy at risk of developing end-stage renal disease. Nefecon has shown positive results in an...

2014-05-13 08:33:02

HAYWARD, Calif., May 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the first quarter ended March 31, 2014. First Quarter 2014 Financial Results: Net loss for the first quarter ended March 31, 2014 was $7.9 million, compared to $7.6 million for the same period in 2013. Operating expenses for the three months ended March 31, 2014 increased to $7.6 million from $6.9 million in the same period of...

2014-01-13 04:20:59

STOCKHOLM, January 13, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon(R) (http://www.nefigan.net). Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety...

2013-09-23 23:34:17

Although Acthar Gel has numerous indications and data suggest that it may be a viable treatment option for resistant nephrotic syndrome, there remains a lack of guidelines on its use. Portland, OR (PRWEB) September 23, 2013 During a recent webinar hosted by AllMed Healthcare Management, Dr. James Wood, board-certified internist and nephrologist, gave an in-depth presentation on the use of Acthar Gel for the treatment of nephrotic syndrome. Although Acthar Gel has numerous indications and...

2013-03-25 23:02:35

Kaylee Henriquez knew that she was in for a difficult pregnancy. She was living with glomerulonephritis, an extremely rare kidney disease. Great Neck, NY (PRWEB) March 25, 2013 Kaylee Henriquez knew that she was in for a difficult pregnancy. She was living with glomerulonephritis, an extremely rare kidney disease that resulted in massive swelling and very high blood pressure. She fell into the high-risk pregnancy category because her kidneys were failing. Refusing to give up on the idea of...

2012-05-03 19:03:15

The American College of Rheumatology (ACR) has issued newly created guidelines for the screening, treatment, and management of lupus nephritis–a severe manifestation of systemic lupus erythematosus (SLE) where the disease attacks the kidneys. Previously, only general guidelines for SLE existed for clinicians. The guidelines, available today in Arthritis Care & Research, are specific to lupus nephritis and include methods for identifying renal disease, newer therapies, and treatment...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related